Follow
kenneth o'byrne
kenneth o'byrne
Queensland University of Technology; Princess Alexandra Hospital; Translational Research Institute
Verified email at qut.edu.au
Title
Cited by
Cited by
Year
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer
M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
N engl J med 375, 1823-1833, 2016
74312016
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...
New England Journal of Medicine 368 (25), 2385-2394, 2013
36842013
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ...
Journal of clinical oncology 31 (27), 3327-3334, 2013
32372013
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ...
New England journal of medicine 378 (2), 113-125, 2018
31132018
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...
New England Journal of Medicine 377 (20), 1919-1929, 2017
29712017
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ...
New England Journal of Medicine 376 (7), 629-640, 2017
26702017
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...
New England Journal of Medicine 378 (24), 2288-2301, 2018
24302018
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, ...
New England Journal of Medicine 378 (22), 2093-2104, 2018
23472018
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
20482017
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
New England Journal of Medicine 379 (24), 2342-2350, 2018
19322018
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast …
M Marty, F Cognetti, D Maraninchi, R Snyder, L Mauriac, M Tubiana-Hulin, ...
Journal of clinical oncology 23 (19), 4265-4274, 2005
18772005
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
R Pirker, JR Pereira, A Szczesna, J Von Pawel, M Krzakowski, R Ramlau, ...
The Lancet 373 (9674), 1525-1531, 2009
17412009
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised …
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The lancet oncology 16 (2), 141-151, 2015
15062015
Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ...
New England Journal of Medicine 381 (21), 2020-2031, 2019
14332019
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ...
New England Journal of Medicine 382 (1), 41-50, 2020
12102020
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ...
The Lancet Oncology 17 (5), 577-589, 2016
9972016
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor …
B Morgan, AL Thomas, J Drevs, J Hennig, M Buchert, A Jivan, ...
Journal of Clinical Oncology 21 (21), 3955-3964, 2003
7352003
Chronic immune activation and inflammation as the cause of malignancy
KJ O'Byrne, AG Dalgleish
British journal of cancer 85 (4), 473-483, 2001
7062001
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery …
T Treasure, L Lang-Lazdunski, D Waller, JM Bliss, C Tan, J Entwisle, ...
The lancet oncology 12 (8), 763-772, 2011
7012011
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England journal of medicine 383 (18), 1711-1723, 2020
6642020
The system can't perform the operation now. Try again later.
Articles 1–20